Please assess the completion status of the following clinical trial:

Trial Title: Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of PMF or Post PV/ET-MF~* Requires myelofibrosis therapy, in the opinion of the investigator~* High risk OR intermediate-2 risk defined by dynamic international prognostic scoring system (DIPSS) OR intermediate-1 risk defined by DIPSS and associated with symptomatic splenomegaly and/or hepatomegaly~* Transfusion dependent at baseline, defined as ≥ 4 U red blood cell (RBC) transfusion in the 8 weeks prior to first dose of MMB~* Acceptable organ function as evidenced by the following:~  * Platelet Count ≥ 50 x 10\^9/L~ * Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 3 x upper limit of normal (ULN) or AST or ALT ≤ 5 x ULN if liver is involved by disease process as judged by the investigator~ * Serum creatinine ≤ 2.0 mg/dL or calculated creatinine clearance of ≥ 60 mL/min~ * Direct bilirubin ≤ 2.0 x ULN~* Life expectancy of \> 24 weeks~* Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception~* Lactating females must agree to discontinue nursing before MMB administration~* Able to understand and willing to sign the informed consent form~Key Exclusion Criteria:~* Prior splenectomy~* Splenic irradiation within 3 months prior to the first dose of MMB~* Prior treatment with MMB~* Known positive status of human immunodeficiency virus (HIV)~* Chronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B and C), or hepatitis B or C carrier~* Use of strong cytochrome P450 3A4 (CYP3A4) inducer within 2 weeks prior to the first dose of MMB~* Uncontrolled intercurrent illness per protocol~* Treatment with a Janus kinase (JAK) inhibitor within 21 days of the planned first dose of MMB~* Presence of peripheral neuropathy ≥ Common Terminology Criteria for Adverse Events (CTCAE) Grade 2~* Unwilling or unable to undergo a MRI per requirements in the study protocol~* Unwilling to consent to genomics sampling~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Momelotinib (Type: EXPERIMENTAL): MMB for 24 weeks (± 7 days)

Based on this trial design, predict the completion outcome and termination type (if applicable).